Time filter

Source Type

Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRADEV-4-2014-2015 | Award Amount: 9.04M | Year: 2015

Marine (blue) biotechnology is the key to unlocking the huge economic potential of the unique biodiversity of marine organisms. This potential remains largely underexploited due to lack of connectivity between research services, practical and cultural difficulties in connecting science with industry, and high fragmentation of regional research, development and innovation (RDI) policies. To overcome these barriers, EMBRIC (European Marine Biological Resource Infrastructure Cluster) will link biological and social science research infrastructures (EMBRC, MIRRI, EU-OPENSCREEN, ELIXIR, AQUAEXCEL, RISIS) and will build inter-connectivity along three dimensions: science, industry and regions. The objectives of EMBRIC are to: (1) develop integrated workflows of high quality services for access to biological, analytical and data resources, and deploy common underpinning technologies and practices; (2) strengthen the connection of science with industry by engaging companies and by federating technology transfer (TT) services; (3) defragment RDI policies and involve maritime regions with the construction of EMBRIC. Acceleration of the pace of scientific discovery and innovation from marine bioresources will be achieved through: (i) establishment of multidisciplinary service-oriented technological workflows; (ii) joint development activities focusing on bioprospection for novel marine natural products, and marker-assisted selection in aquaculture; (iii) training and knowledge transfer; (iv) pilot transnational access to cluster facilities and services. EMBRIC will also connect TT officers from contrasted maritime regions to promote greater cohesion in TT practices. It will engage with policy-makers with the aim of consolidating a perennial pan-European virtual infrastructure cluster rooted in the maritime regions of Europe and underpinning the blue bioeconomy.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-03-2016-2017 | Award Amount: 4.97M | Year: 2017

The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society. The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are: INFRAFRONTIER Business Plan2.0, and business models for all services Stable legal framework built on the INFRAFRONTIER legal entity INFRAFRONTIER annual stakeholder conferences Customised mouse model and secondary phenotyping pilot services INFRAFRONTIER advanced training schools in mouse phenogenomics Reengineered EMMA Database2.0 system Annotated mouse models of human diseases Quality management system for the legal entity INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.35M | Year: 2015

ENLIGHT-TEN is a European Network Linking Informatics and Genomics of Helper T cells: our mission is to provide cross-disciplinary training in cellular immunology and big data analysis such that we train a new generation of researchers to fully exploit the power of emerging technological platforms. Our network of TEN beneficiaries combines T cell expertise with state-of-the-art technologies such as next generation sequencing (NGS), bioinformatics, multi-colour flow cytometry, preclinical models and tailored genome editing. Trainees will acquire a comprehensive knowledge in T cell immunology and the capacity to generate and interrogate big data sets as well as expertise in identifying novel biomarkers and developing therapeutic concepts. As such the training programme will provide an ideal stepping-stone for creative and innovative early stage researchers (ESRs) to enter and strengthen Europes academia as well as pharmaceutical and bioinformatics companies. The research focus of the network lies in the identification of extrinsic and intrinsic factors that control development, differentiation and plasticity of helper T cell subsets with particular emphasis on how T cell differentiation impacts on human diseases. The generation of large data sets is an emerging and challenging field, and there is high demand in both the academic sector as well as pharmaceutical companies for researchers to be able to analyse, integrate and exploit this rich source of information. ENLIGHT-TEN will combine the individual strengths of innovative laboratories and enterprises from complementary disciplines to provide unique interdisciplinary training for 13 ESRs, placing them at the forefront of this emerging field. Trainees will be empowered to perform cutting-edge analysis of the steadily increasing number of different T cell subsets, which play highly diverse and critical roles in the development of autoimmune diseases, making them a key target for pharmaceutical companies.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.96M | Year: 2016

Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe diseases, especially in children, immunocompromised individuals, and elderly. There are currently no safe vaccines against herpesvirus infections and current treatments are not satisfactory. With new insights into the molecular basis for diseases caused by immunodeficiency, and with the increasing numbers of elderly in Europe, there is now an unmet demand for improved treatments of herpesvirus infections. Combined with the progress in basic herpesvirus research, this calls for education of a new generation of scientists with strong research skills, advanced insights into disease mechanisms, and understanding of how industry brings innovative research into the market. In this application we propose an interactive education program for early stage researchers (ESR) in leading European laboratories, hospitals, and biotech companies. The focus will be on the virology and immunology of herpesvirus infections in the context of basic research as well as application of research-acquired knowledge. Our program will prepare the ESRs to manage goal-oriented interactions between academia, the clinics, and the biotech industry. The ESRs will acquire broad theoretical and methodological expertises involving several sectors to obtain the skills required for overcoming the cultural gaps From Bench to Bedside and From Discovery to Innovation. This can only be achieved through a network-based approach. We propose to develop a platform to educate the next generation of scientists to solve the outstanding problems in prevention and treatment of herpesvirus infections. The ESRs will be ideally trained to translate cutting-edge discoveries to novel products and to innovative treatment serving the European people, and hence to improve handling of present and emerging health challenges, as well as to foster the European biopharmaceutical industry sector.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 6.00M | Year: 2017

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.


Crouse J.,ETH Zurich | Kalinke U.,Helmholtz Center for Infection Research | Oxenius A.,ETH Zurich
Nature Reviews Immunology | Year: 2015

Type I interferons (IFNs) are pro-inflammatory cytokines that are rapidly induced in different cell types during viral infections. The consequences of type I IFN signalling include direct antiviral activity, innate immune cell activation and regulation of adaptive immune responses. In this Review, we discuss recent conceptual advances in our understanding of indirect and direct regulation of T cell immunity by type I IFNs, which can either promote or inhibit T cell activation, proliferation, differentiation and survival. This regulation depends, to a large extent, on the timing of type I IFN exposure relative to T cell receptor signalling. Type I IFNs also provide activated T cells with resistance to natural killer cell-mediated elimination. © 2015 Macmillan Publishers Limited. All rights reserved.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.00M | Year: 2015

Many therapeutic targets are shielded behind biological barriers, limiting the possibility to reach them with conventional drugs or diagnostic probes. Biological barriers are even more problematic for most biological pharmaceutics, such as recombinant proteins, antibodies and gene therapeutics. The most promising solution to this challenge is the use of nano-vehicles for specific targeting and delivery. The aim of NABBA is to form European early stage researchers (ESR) with cutting-edge scientific knowledge in the field of nanoparticles (NP) for biomedical application, able to cross biological barriers. For this aim the project will train ESRs, focusing on key aspects of nanobiotechnology: (i) design and chemical synthesis of different types of NPs, (ii) related techniques of detection and characterization, (iii) strategies of loading, targeting and delivery of drugs or diagnostic probes; (iv) proof of principle of pharmacological activity including pharmacokinetics and biodistribution. As a peculiar feature of NABBA, strong emphasis will be devoted to molecular mechanisms ruling biological barriers under physiological and pathological conditions, in order to develop novel nano-technological expedients for their crossing. Strong emphasis will be devoted to advanced chemistry issues, enabling new synthetic strategies either for NP assembly or functionalization. Different biological barriers will be addressed. ESRs will strongly benefit from a network of internationally recognized scientists in the field of chemistry, nanobiotechnology and nanomedicine, and the participation of companies with relevant interests and expertises in the field. The planned cooperation programs between Academia and Industries will allow the circulation of ESRs and this will give them the opportunity for to get acquainted with the most advanced research in the field, the most sophisticated technologies and the most advanced Industrial manufacturing platforms and innovative strategies.

Loading Helmholtz Center for Infection Research collaborators
Loading Helmholtz Center for Infection Research collaborators